Biogen News and Research

RSS

MS sufferers relieved as drug Tysabri goes back on the market

The Food and Drug Administration in the U.S. has given it's approval for the multiple sclerosis drug Tysabri to be put back on the market.

6 Jun 2006

FDA approves resumed marketing of Tysabri

The Food and Drug Administration (FDA) today approved an application for resumed marketing of Tysabri (natalizumab) subject to a special restricted distribution program.

5 Jun 2006

MS sufferers lobby for return of Tysabri

Despite the deaths of two people among the thousands treated with a promising multiple sclerosis drug, MS patients are trying to persuade the U.S. government to allow the drug back onto the market.

8 Mar 2006

Extensive study of natalizumab

Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was linked to three cases of a serious brain infection in large clinical trials halted in early 2005.

7 Mar 2006

Trials on MS drug Tysabri renews hope for sufferers

According to the results of two new trials the multiple sclerosis (MS) drug Tysabri significantly reduces the progression of the disease.

5 Mar 2006

FDA approves Rituxan (Rituximab)

Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.

1 Mar 2006

Withdrawn MS drug works for Crohn's sufferers

Researchers say that a multiple sclerosis drug that was withdrawn from the market for safety reasons, has shown some effectiveness against the painful bowel disorder Crohn's disease.

3 Nov 2005

Multiple sclerosis drug Tysabri could be back on the market later in the year

The drug Tysabri which was approved by the Food and Drug Administration (FDA) for the treatment of multiple sclerosis in November 2004, was taken off the market in late February, after two cases of progressive multifocal leukoencephalopathy, or PML, appeared in patients given the drug during clinical trials.

9 Jun 2005

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Researchers at the Keck School of Medicine of the University of Southern California and colleagues have found a way to streamline a new form of treatment for patients with non-Hodgkin's lymphoma.

18 May 2005

Increased scrutiny of new multiple sclerosis-fighting drugs after Tysabri withdrawal

The removal of Tysabri from the market soon after its introduction is expected to increase scrutiny of other similar drugs in development for multiple sclerosis (MS), says ECRI, a leading, independent health services research agency.

11 Apr 2005

New MS drug withdrawn from the market

Two patients involved in clinical trials of Tysabri, have contracted a rare and fatal disease, Elan’s multiple sclerosis (MS); one has already died. Withdrawal of the drug, eliminates all hope that it will be allowed back on the market this year, or ever.

8 Mar 2005

Australian biotech, Bionomics acquires central nervous system (CNS) business

Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.

6 Mar 2005

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004

Scientists have sped up a common jumping gene found in the human genome

Johns Hopkins scientists have transformed a common "jumping gene" found in the human genome into one that moves hundreds of times more often than normal in mouse and human cells.

20 May 2004

The number of antibody-based medicines will climb dramatically

The number of antibodies in clinical development has leapt over the past six years and in 2004 hundreds are currently making their way through trials in what surely will be a spate of new product introductions beginning in 2004 and continuing over the next 10 years.

15 May 2004

FDA approves new drug Enbrel for psoriasis

The U.S. Food and Drug Administration has approved the biologic drug etanercept (brand name Enbrel) to treat chronic, moderate to severe plaque psoriasis in adults.

1 May 2004